Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.62 |
| ▸ | PPARG known ✓ | P37231 | 6/20 | 0.55 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.55 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.55 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.55 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | PLG | P00747 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1802789 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2220731 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL125909 | 0.97 | TSHR (0.75) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL3067489 | 0.97 | TSHR (0.75) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1329236 | 0.97 | LMNA (0.69) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL25255715 | 0.97 | TSHR (0.75) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL12849553 | 0.97 | TSHR (0.75) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL227903 | 0.97 | TSHR (0.75) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL20651676 | 0.97 | TSHR (0.75) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL19599369 | 0.97 | TSHR (0.75) | TSHRLMNANFKB1PMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-15 | — | — | US | claimed |
| US-20200080122-A1 | Cleavable Nucleotide Analogs and Uses Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2020-03-12 | — | — | US | claimed |
| WO-2018102554-A1 | CLEAVABLE NUCLEOTIDE ANALOGS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-06-07 | — | — | WO | claimed |
| EP-4400121-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240180150-A1 | Green Closed Loop Bio-waste Refining Process For Producing Smart Active Extracts and Delivery Systems for Their Application | CELLACURE LLC (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2023077038-A9 | SYSTEMS AND METHODS TO IDENTIFY MHC-ASSOCIATED ANTIGENS FOR THERAPEUTIC INTERVENTION | GENENTECH, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3515476-B1 | FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTIEPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER | AMAL THERAPEUTICS SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| EP-3429618-B1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-3693009-B1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024005123-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2024-01-04 | — | — | WO | disclosed |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2002100900-A2 | HUMAN RECOMBINANT ANTIBODY AGAINST THE HEPATITIS C (HCV) NON STRUCTURAL NS3 PROTEIN, NUCLEIC ACID AND USES THEREOF | BIOSTRANDS S.R.L. (IT) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002098455-A2 | PRODUCTION OF RECOMBINANT HUMAN ARYLSULFATASE A | HEMEBIOTECH A/S (DK) | 2002-12-12 | — | — | WO | disclosed |
| EP-0339080-B1 | IMPLANTATION OF PROSTHETIC DEVICES | CHIRON OPHTHALMICS INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| US-5171318-A | Coating of surface with fibronectin | CHIRON OPHTHALMICS, INC. (US) | 1992-12-15 | — | — | US | disclosed |
| US-5053388-A | Coating corneal incision with protein crosslinking compound, applying extra cellular matrix material, both with carriers | CHIRON OPHTHALMICS, INC. (US) | 1991-10-01 | — | — | US | disclosed |
| EP-0339080-A4 | IMPLANTATION OF PROSTHETIC DEVICES. | CHIRON OPHTHALMICS INC (US) | 1989-11-07 | — | — | EP | disclosed |
| EP-0339080-A1 | IMPLANTATION OF PROSTHETIC DEVICES | CHIRON OPHTHALMICS INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989004172-A1 | WOUND HEALING COMPOSITION AND METHOD | CHIRON OPHTHALMICS INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| WO-1989004153-A1 | IMPLANTATION OF PROSTHETIC DEVICES | CHIRON OPHTHALMICS INC. (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200080122-A1 | Cleavable Nucleotide Analogs and Uses Thereof | TYMP, DUT, NT5C3B | SLC6A2 2576/4885SLC6A3 3315/4885PPARG 3408/4885 |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | TYMP, DUT, NT5C3B | SLC6A2 2576/4885SLC6A3 3315/4885PPARG 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.